is that means the entecavir will become chaper and cheaper by this year 2013?
$250 million of USD is only USA market. Take into account rest of the world and there will be billions in just a month.
Baraclude generates $250+ million USD per year for BMS. The drug is patented for 10 years so thats rougly $2.5 billion USD for BMS.
It would be in thier best interest to develop better drugs for the Hepatitis B market and have them available after the patent expires. Considering thier is a lot of potential to treat people, drug manufacturers should jump on the Hepatitis B market.
so ,
the price will reduce sooon .. every hbver can get the medicine all over the world ..
so will baraclude be forbidden as a consequences of this invalidation ?
This is a good wake up call for Bristol Myers to by or partner with Replicor.